<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="description" content="WTO | dispute settlement - the disputes - DS583">
<meta name="keywords" content="www.wto.org, World Trade Organization, world trade, trade disputes, #TradeDisputes,  ministerial, WTO publications, intellectual property,  government procurement, goods, services, economic research, Statistics, OMC, about the WTO, trade,  agriculture, textiles, services, intellectual property, anti-dumping, subsidies, environment, investment, research and analysis, international trade, trade topics, principles of the trading system">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@wto">
<meta name="twitter:creator" content="@wto">
<meta name="twitter:title" content="WTO | dispute settlement - DS583: Turkey - Certain Measures Concerning the Production, Importation and Marketing of Pharmaceutical Products">
<meta name="twitter:description" content="On 2 April 2019, the European Union requested consultations with Turkey regarding various measures concerning the production, importation and marketing of pharmaceutical products. The measures identified by the European Union include the following alleged acts: a localisation requirement, a technology transfer requirement, an import ban on localised products, and a prioritization measure.">
<meta name="twitter:image" content="https://www.wto.org/images/img_index/photos/disputesjustice2016_md.jpg">
<meta property="og:url" content="https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds583_e.htm" />
<meta property="og:type"  content="article" />
<meta property="og:title" content="WTO | dispute settlement - DS583: Turkey - Certain Measures Concerning the Production, Importation and Marketing of Pharmaceutical Products" />
<meta property="og:description" content="On 2 April 2019, the European Union requested consultations with Turkey regarding various measures concerning the production, importation and marketing of pharmaceutical products. The measures identified by the European Union include the following alleged acts: a localisation requirement, a technology transfer requirement, an import ban on localised products, and a prioritization measure." />
<meta property="og:image" content="http://www.wto.org/images/img_index/disputesjustice2016_md.jpg" />
<meta property="og:image:secure_url" content="https://www.wto.org/images/img_index/photos/disputesjustice2016_md.jpg" />
<meta property="og:image:type" content="image/jpeg" />
<title>WTO | dispute settlement - the disputes - DS583</title>
<script language="JavaScript1.2" type="text/javascript" src="/library/imrdlib.js"></script>
<script language="JavaScript1.2" type="text/javascript" src="/library/countrylib.js"></script>
<script language="JavaScript1.2" type="text/javascript" src="/library/rollovertips.js"></script>

<script language="Javascript1.2" type="text/javascript" src="/library/wtomenus/jquery.min.js"></script>
<script language="Javascript1.2" src="/library/wtomenus/jkmegamenu.js" type="text/javascript">
/** jQuery Mega Menu- Visit JavaScript Kit at http://www.javascriptkit.com/ for full source code **/
</script>
<script language="javascript1.2" type="text/javascript" src="/library/wtomenus/common_data_e.js"></script>
<script language="Javascript1.2" type="text/javascript" src="/library/news/news_vars_e.js"></script> 
<script language="Javascript1.2" type="text/javascript" src="/library/events/events_code.js"></script>
<script language="Javascript1.2" type="text/javascript">
// load photo gallery & news items for this year & last year
	var now = new Date();
	document.write("<script language=\"Javascript1.2\" type=\"text/javascript\" src=\"/library/news/news_" + (now.getFullYear()-1) + "_e.js\"><\/script>");
	document.write("<script language=\"Javascript1.2\" type=\"text/javascript\" src=\"/library/news/news_" + now.getFullYear() + "_e.js\"><\/script>");
	document.write("<script language=\"Javascript1.2\" type=\"text/javascript\" src=\"/library/events/meetings_" + now.getFullYear() + ".js\"><\/script>");
	document.write("<script language=\"Javascript1.2\" type=\"text/javascript\" src=\"/library/events/meetings_" + (now.getFullYear()-1) + ".js\"><\/script>");
</script>
<script language="Javascript1.2" type="text/javascript" src="/library/news/current_news_e.js"></script>
<script language="Javascript1.2" type="text/javascript" src="/library/disputes/dispute_arrays_e.js"></script>
<script language="Javascript1.2" type="text/javascript" src="/library/disputes/ds_dates_array.js"></script>
<script language="Javascript1.2" type="text/javascript" src="/library/disputes/dispute_code.js"></script>
<script language="Javascript1.2" type="text/javascript" src="/library/generic_dol_script_html.js"></script>
<script language="JavaScript1.2" type="text/javascript">
<!-- 
// variable for dispute number
var dsNumber = "583";
//-->
</script>

<!-- specify language used for page -->
<meta http-equiv="Content-Language" content="en">
<!-- link to the stylesheet for the page -->
<link rel="stylesheet" type="text/css" href="/library/styles/tratop_styles.css">
<!-- javascript for menu functions -->
<script language="JavaScript1.2" type="text/javascript">
<!--
// set variables for use wih drop down menus
	var wto_string = "";                            // Path 
	var wto_language = "e";             		// Language for menu (e,f or s)
	var old_browser = false;
	var this_page = location.href;

// get the relative path
	var wto_folders = this_page.split("/");
	var pagename = wto_folders[wto_folders.length - 1];
	var wto_dotslash = "";//-->
</script>


</head>

<body  link="#808080" vlink="#808080">
<!-- Constrain the page display within the window -->
<div id="page" class="pagestyle" >
<!-- Display a banner on the page -->
<div id="banner">
<noscript><h1>WORLD TRADE ORGANIZATION</h1>
<p class="menudefaulttext"><a href="http://www.wto.org/index.htm" class="menudefaulttext">Home</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/thewto_e/thewto_e.htm" class="menudefaulttext">About WTO</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/news_e/news_e.htm" class="menudefaulttext">News &amp; events</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/tratop_e/tratop_e.htm" class="menudefaulttext">Trade topics</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm" class="menudefaulttext">WTO membership</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/res_e/res_e.htm" class="menudefaulttext">Documents &amp; resources</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/forums_e/forums_e.htm" class="menudefaulttext">External relations</a></p>
<p class="bannertoptext"><a href="http://www.wto.org/english/info_e/cont_e.htm" class="bannertoptext">Contact us</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/info_e/site2_e.htm" class="bannertoptext">Site map</a>&nbsp; |&nbsp; <a href="http://www.wto.org/english/info_e/site_e.htm" class="bannertoptext">A-Z</a>&nbsp; |&nbsp; <a href="http://search.wto.org/search?site=English_website&amp;proxystylesheet=english_frontend&amp;output=xml_no_dtd&amp;client=english_frontend&amp;proxycustom=%3CADVANCED/%3E&amp;numgm=5" class="bannertoptext">Search</a></p>
</noscript>
</div>  <!-- end of banner -->
<!-- Display the content on the page -->
<div id="mainContainer">
<a name="skip" id="skip"></a>

<noscript><p class="menulanguagetext" align="right">
                       
                          <a class="menulanguagetext" href="/spanish/tratop_s/dispu_s/cases_s/ds583_s.htm">español</a>&nbsp;
                          <a class="menulanguagetext" href="/french/tratop_f/dispu_f/cases_f/ds583_f.htm">français</a></p></noscript>
<div id="breadcrumbsDiv"><ol><li><a href="/index.htm">home</a></li><li><a href="/english/tratop_e/tratop_e.htm">trade
          topics</a></li><li><a href="/english/tratop_e/dispu_e/dispu_e.htm">dispute
          settlement</a></li><li><a href="/english/tratop_e/dispu_e/dispu_status_e.htm">the disputes</a></li><li><script type="text/javascript" language="javascript">
<!--  // write ds number in breadcrumbs
	document.write('<span>ds' + dsNumber + '</span>');
//-->
</script></li></ol></div>
<div class="introDiv">
<div class="introImgDiv">
        
              <a href="/english/tratop_e/tratop_e.htm" onMouseOver="writetxt('Issues covered by the WTO&rsquo;s committees and agreements')" data-content="Issues covered by the WTO&rsquo;s committees and agreements" data-toggle="tooltip" onMouseOut="writetxt(0)"> <img src="/images/top_logo.gif" width="160" height="160" border="0"></a></div>
<div class="introTextDiv"><p class="kickertext"><strong>DISPUTE SETTLEMENT</strong></p>
<h1><span class="dsnumber">DS<script>document.write(dsNumber);</script>:</span>   Turkey &mdash; Certain Measures Concerning the Production, Importation and Marketing of Pharmaceutical Products</h1>
       </div></div>

<div class="mainDiv">
<div class="leftCol"><p class="parasmalltext">
        This summary has been prepared by the Secretariat under its own responsibility. The summary is for general information only and is not intended to affect the rights and obligations of Members.</p>
        <p align="right" class="parasmalltext">&nbsp;&nbsp;</p>
        <h4>See also:</h4>
<div id="leftcol1pagesum"></div>
<ul>
<li><a href="javascript:disputeNewsLink(dsNumber)" class="parasmallcolourtext">News items about this dispute</a></li>
<li><a href="/english/thewto_e/whatis_e/tif_e/disp1_e.htm" class="parasmallcolourtext">The basics: how disputes are settled in WTO</a></li>
<li><a href="/english/tratop_e/dispu_e/disp_settlement_cbt_e/signin_e.htm" class="parasmallcolourtext">Computer based training on dispute settlement</a></li>
<li><a href="/english/docs_e/legal_e/legal_e.htm#dispute" class="parasmallcolourtext">Text of the Dispute Settlement Understanding</a></li>
<li><img src="/images/img_index/twitter.png" style="width: 18px">&nbsp;<a href="https://twitter.com/hashtag/TradeDisputes?src=hash" class="parasmallcolourtext"  target="_blank" data-content="Opens in a new window" data-toggle="tooltip">#TradeDisputes</a></li>
</ul>
</div>
<div class="centerCol"><a href="#top" class="backToTop">back&nbsp;to&nbsp;top</a><h2 id="status">Current status</h2>
    <div class="well">
        <ul class="mb0">
<script language="JavaScript1.2" type="text/javascript">
<!--  // call javascript function to display short title for the dispute
	showCurrentStatus(dsNumber);
//-->
</script>
</ul>
    </div>
      <p align="left" class="paranormaltext">&nbsp;</p>
      <a href="#top" class="backToTop">back&nbsp;to&nbsp;top</a><h2 id="facts">Key facts</h2>
<!-- Start key facts table -->
<table id="keyFactsTbl" class="contentTable doltable">
</table>
<!-- end key facts table -->
<p>&nbsp;</p>
<a href="#top" class="backToTop">back&nbsp;to&nbsp;top</a>
<h2 id="documents">Latest document</h2>
            <div id="dolDocsBox"> </div>
    		<script>document.write("<p><a class=\"link-blue\" href=\"#\"  onClick=\"f_submit('(@meta_Symbol WT/DS" + dsNumber + "/*)','1');return false\">View all documents&nbsp;<i class=\"icon-r-arrow\"></i></a></p>");</script>
        <p align="left" class="paranormaltext">&nbsp;&nbsp;</p>
        <a href="#top" class="backToTop">back&nbsp;to&nbsp;top</a><h2 id="summary">Summary of the dispute to date</h2>

        <p align="left" class="paranormaltext">The summary below was up-to-date at  
          <script language="JavaScript1.2" type="text/javascript">
<!--  // call javascript function to display last updated date
	showUpdateDate(dsNumber);
//-->
          </script>
		
		<i class="icon-info blue" data-container="body" data-content="Summaries are updated regularly, but the Documents Online search in right column may retrieve more recent documents" data-original-title="" data-placement="bottom" data-toggle="popover"></i><br><span id ="centrecol1pagesum"></span></p>
        <h3>Consultations</h3>
         <p class="paranormaltext"><strong>Complaint by  the European Union</strong> <!--(See also <a href="/english/tratop_e/dispu_e/cases_e/ds..._e.htm">DS...</a>)--></p>
        <p align="left">On 2 April 2019, the European Union requested  consultations with Turkey regarding various measures concerning the production,  importation and marketing of pharmaceutical products. The measures identified  by the European Union include the following alleged acts: a localisation  requirement, a technology transfer requirement, an import ban on localised  products, and a prioritization measure.</p>

        <p align="left">The European Union claimed that: </p>
         <ul>
           <li>The localisation requirement and the  prioritization measure appear to be inconsistent with Article&nbsp;III:4 of the  GATT 1994. <br>
&nbsp;           </li>
           <li>The localisation requirement, the technology  transfer requirement, and the prioritization measure appear to be inconsistent  with Articles X:1 and X:3(a) of the GATT 1994.<br>
&nbsp;           </li>
           <li>All four categories of challenged measures  appear to be inconsistent with Article X:2 of the GATT 1994.<br>
&nbsp;           </li>
           <li>The import ban on localised products appears to  be inconsistent with Article XI:1 of the GATT 1994.<br>
&nbsp;           </li>
           <li>The localisation requirement appears to be  inconsistent with Article 2.1 of the TRIMS&nbsp;Agreement and Article 3.1(b) of  the SCM Agreement.<br>
&nbsp;           </li>
           <li>The technology transfer requirement appears to  be inconsistent with Articles 3.1, 27.1, 28.2, 39.1 and 39.2 of the TRIPS  Agreement. </li>
         </ul>
         <p>The European Union submitted, together with its  consultations request, a statement of available evidence pursuant to Article  4.2 of the SCM Agreement.</p>
        <p align="left">On 18 April 2019, the United States  requested to join the consultations. </p>
<p class="paranormaltext">&nbsp;</p>
<h3>Panel  and Appellate Body proceedings</h3>
<p align="left">On 2 August 2019, the European Union requested the  establishment of a Panel. At its meeting on 15&nbsp;August&nbsp;2019, the DSB  deferred the establishment of a panel.</p>
<p align="left">At its meeting on 30 September 2019, the  DSB established a panel. Brazil, Canada, China, India, Indonesia, Japan, the  Russian Federation, Switzerland, Ukraine and the United States reserved their  third-party rights.</p>
<p class="paranormaltext">On 4 March 2020, the European Union  requested the Director-General to compose the panel. On 17&nbsp;March&nbsp;2020,  the Director-General composed the panel.</p>
<p class="paranormaltext">On 15 September 2020, the Chair of the  panel informed the DSB that due to the delays caused by the global COVID-19 pandemic,  the panel did not expect to issue its final report to the parties before the  second half of 2021. The Chair apprised the DSB that the  report would be available to the public once it was circulated to the Members  in all three official languages, and that the date of circulation depended on  completion of translation.</p>
<p class="paranormaltext">The confidential final report was issued to the parties on 11 November  2021, and the panel informed the parties that circulation of the report was  expected in mid-January 2022. On  22 December 2021, the Chair of the panel informed the DSB that the panel had granted the European Union's request of 20 December  2021, to which Turkey indicated that it did not object on the same day, that  the panel suspend its work pursuant to Article 12.12 of the DSU until and  including 21 January 2022. The Chair of the panel informed the DSB on 21 January 2022, 10 February  2022 and 24 February 2022 that the panel had granted the European Union&rsquo;s  subsequent requests for extensions of the suspension of the panel&rsquo;s work.</p>
<p align="left">On 22 March 2022, the parties jointly  communicated to the panel and to the DSB that they had agreed on procedures for  arbitration under Article 25 of the DSU. Through these agreed procedures, the  European Union and Turkey jointly requested the Panel to suspend its work  indefinitely pursuant to Article&nbsp;12.12 of the DSU, except to the extent  necessary to effect certain joint requests of the parties. The Panel accepted  this request.</p>
<p align="left"> Moreover, the parties requested the  panel to transmit the final report to the parties and third parties, without  circulating it, and to allow the parties to disclose the report if they  resorted to arbitration under Article 25 in accordance with their agreed  procedures. The panel granted the parties' requests. It therefore transmitted  its report to the parties and third parties, and agreed that the report would  no longer be confidential if the parties resorted to arbitration under Article  25 in accordance with their agreed procedures.&nbsp; </p>
<p align="left">&nbsp;</p>
<h3> Arbitration under Article 25 of the  DSU</h3>
<p align="left"> In the agreed  procedures for arbitration under Article 25 of the DSU , the parties indicated  that they had mutually agreed pursuant to Article 25.2 of the DSU       &ldquo;to  enter into arbitration under Article 25 of the DSU to decide any appeal from  any final report as issued to the parties in dispute DS583.&rdquo;</p>
<p class="paranormaltext">&nbsp;</p>
       <p class="paranormaltext"><a  id="art25" name="art25"></a>On 25 April 2022, Turkey filed a notice of recourse to Article 25 under  those agreed procedures. In their agreed procedures, the parties refer to this  notice as a Notice of Appeal. This notice was circulated to the DSB on 28 April  2022. The notice includes the full text of the report transmitted by the panel  to the parties, which is thereby made public even though it has not been  circulated by the panel for the purposes of Article 16 of the DSU. The  following is a summary of the panel report as included in Turkey&rsquo;s notice of  recourse to Article 25:</p>
<div aria-multiselectable="true" class="panel-group accordion" role="tablist">
   <div class="panel panel-default">
      <div class="panel-heading" id="headingOne" role="tab">
          <h4 class=""><a aria-controls="collapseA" aria-expanded="false" class="collapsed" data-parent="#accordion" data-toggle="collapse" href="#collapseA" role="button">Summary of key findings</a></h4>
      </div>
      <div aria-labelledby="headingOne" class="panel-collapse collapse" id="collapseA" role="tabpanel">
          <div class="panel-body">


              <p>The European Union challenged three measures, which it described as  follows: </p>
                          <ol style="list-style: lower-alpha">
                            <li>a  &ldquo;localisation requirement&rdquo; whereby Turkey requires foreign producers  to commit to localise in Turkey their production of certain pharmaceutical  products and if such commitments are not given, are not accepted by Turkish  authorities, or are not fulfilled, the pharmaceutical products concerned are  excluded from the scheme for the reimbursement of the pharmaceutical products  sold by pharmacies to patients operated by Turkey's social security system;</li>
                            <li>an  &ldquo;import ban on localised products&rdquo;, which is the localisation  requirement applied in conjunction with certain rules for approving the  importation and marketing of pharmaceutical products; and </li>
                            <li>a  &ldquo;prioritization measure&rdquo; whereby Turkey gives priority to the review  of applications for inclusion of domestic pharmaceutical products in the list  of products covered by the reimbursement scheme, as well as with respect to any  pricing and licensing policies and processes, over the review of the  applications of like imported products.</li>
                          </ol>
              <p>With respect to the localisation requirement: </p>
              <ol style="list-style: lower-alpha">
              <li>the  Panel rejected Turkey's argument that the European Union had failed to  establish the &ldquo;existence&rdquo; and &ldquo;precise content&rdquo; of the  localisation requirement as a single and cohesive measure; </li>
              <li>the  Panel rejected Turkey's argument that, because the government pays the price of  pharmaceutical products in Turkey, the challenged measure involves a  governmental &ldquo;purchase&rdquo; of products covered by the &ldquo;government  procurement&rdquo; derogation in Article III:8(a) of the GATT 1994;</li>
              <li>the Panel  upheld the European Unions' claim that the localisation requirement is  inconsistent with the national treatment obligation in Article III:4 of the  GATT 1994 because it is designed to create a financial incentive for consumers  to select domestically produced pharmaceutical products (the cost of which is  mostly borne by the government) over imported pharmaceutical products (which  over time will cease to be paid for by the government), and thus accords  &ldquo;less favourable treatment&rdquo; to those imported pharmaceutical  products;</li>

                            <li>the Panel  rejected Turkey's affirmative defence that the localisation requirement is  designed to ensure an uninterrupted access to safe, effective and affordable  medicines for the Turkish population, and thus falls within the range of policies  to protect human life and health covered by the general exception in Article  XX(b) of the GATT 1994;</li>
                            <li>the Panel  rejected Turkey's affirmative defence that the localisation requirement is, for  similar reasons, a measure necessary to secure its compliance with certain laws  and regulations requiring Turkey to ensure accessible, effective and  financially sustainable healthcare within the meaning of Article XX(d) of the  GATT 1994; </li>
                            <li>in the  light of these findings, the Panel declined to rule on the European Union's  alternative and conditional claim under Article 3.1(b) of the SCM Agreement;  and </li>
                            <li>the Panel  likewise exercised judicial economy over the European Union's additional claims  under Article&nbsp;2.1 of the TRIMs Agreement and Article X:1 of the GATT 1994.</li>
                          </ol>
              <p>In the light of these findings on the localisation requirement, the  Panel exercised judicial economy over the European Union's claim that the  localisation requirement applied in conjunction with the Turkish rules for  approving the importation and marketing of pharmaceutical products (referred to  by the European Union as the &ldquo;import ban on localised products&rdquo;) is  inconsistent with Article XI:1 of the GATT 1994.</p>
              <p>With respect to the prioritization measure:</p>
<ol style="list-style: lower-alpha">
              <li>the  Panel rejected Turkey's argument that the European Union failed to establish  the existence of an overarching &ldquo;prioritization measure&rdquo; as defined  by the European Union; and</li>
              <li>upheld  the European Union's claim that the prioritization measure is inconsistent with  Article III:4 of the GATT 1994.</li>
            </ol>
          </div>
      </div>
  </div>
</div>

    
    
    <p class="paranormaltext">On 28 April 2022, the Arbitrator was composed.</p>
          <p class="paranormaltext"><a  id="bkmkart25r" name="bkmkart25r"></a>On 21 July 2022, the Arbitrators' Award was issued  to the parties. On 25 July 2022, in accordance with Article&nbsp;25.3 of the  DSU, the Award was notified to the Dispute Settlement Body, the Council for  Trade in Goods, the Committee on Subsidies and Countervailing Measures, and the  Committee on Trade-Related Investment Measures. </p>
<div aria-multiselectable="true" class="panel-group accordion" role="tablist">
   <div class="panel panel-default">
      <div class="panel-heading" id="headingTwo" role="tab">
          <h4 class=""><a aria-controls="collapseB" aria-expanded="false" class="collapsed" data-parent="#accordion" data-toggle="collapse" href="#collapseB" role="button">Summary of key findings</a></h4>
      </div>
      <div aria-labelledby="headingTwo" class="panel-collapse collapse" id="collapseB" role="tabpanel">
          <div class="panel-body">
    	    <p align="left">In the  Arbitration, T&uuml;rkiye challenged the Panel's findings pertaining to the  localisation requirement under Articles&nbsp;III:4, III:8(a), XX(b), and XX(d)  of the GATT 1994.</p>
            <p align="left">With  respect to Articles III:4 and III:8(a) of the GATT 1994: </p>
            <ul>
              <li>The Arbitrators considered that, under Article  III:8(a), &ldquo;procurement by governmental agencies of products purchased for  governmental purposes&rdquo; would typically involve the procurement of products  through a purchase by a governmental agency. However, Article&nbsp;III:8(a)  does not contain an unequivocal requirement to that effect. The Arbitrators did  not foreclose the possibility that, in certain circumstances, the relevant  purchase transaction may be entered into by a non-governmental entity so long  as the products are <em>procured by</em> a governmental agency and procurement is  of products purchased for governmental purposes. The Arbitrators therefore  found that the Panel erred in considering, as a starting point for its  analysis, that Article III:8(a) required a <em>purchase by</em> governmental agencies.</li>
              <li>The Arbitrators concluded that, in this case, there  is no procurement by a governmental agency of pharmaceutical products. </li>
              <li>The Arbitrators upheld, albeit for different  reasons, the Panel's finding that the localisation requirement is not covered  by the government procurement derogation in Article III:8(a), and is therefore  subject to the national treatment obligation in Article&nbsp;III:4 of the GATT  1994 and Article 2.1 of the TRIMs Agreement. The Arbitrators found that the  Panel's finding that the localisation requirement is inconsistent with the  national treatment obligation in Article III:4 of the GATT 1994 remains  undisturbed.</li>
            </ul>
            <p align="left">With  respect to Articles XX(b) and XX(d) of the GATT 1994: </p>
            <ul>
              <li>The Arbitrators did not consider that the Panel erred  in its interpretation of Article&nbsp;XX(b). In particular, the Panel did not erroneously  confuse the &ldquo;design&rdquo; and the &ldquo;necessity&rdquo; steps of the legal  analysis. The Panel also did not set out a legal standard requiring a  substantial degree of probability of risk for assessing whether a measure has  been taken to protect human, animal, or plant life or health, nor did the Panel  introduce any quantitative dimension to the notion of risk to human life or  health that unduly limited the range of public health measures that fall within  the scope of Article&nbsp;XX(b). To the extent that they found no reversible  error in the Panel's interpretation, and taking into account the nature of  T&uuml;rkiye's application claims, the Arbitrators considered that T&uuml;rkiye failed to  establish that the Panel erred in its application of Article XX(b). The  Arbitrators also rejected T&uuml;rkiye's claims under Article 11 of the DSU.</li>
              <li>In light of the manner in which T&uuml;rkiye articulated  its justification for the localisation requirement under Article XX(d), the  Arbitrators considered that it did not constitute legal error for the Panel to  have extended elements of its assessment under Article&nbsp;XX(b) <em>mutatis  mutandis</em> to the analysis of T&uuml;rkiye's defence under Article XX(d).</li>
              <li>The Arbitrators upheld the Panel's finding that  T&uuml;rkiye has not established that the localisation requirement is justified under  Article XX(b) or XX(d) of the GATT 1994.</li>
            </ul>
            <p align="left">The  Arbitrators recalled that, pursuant to the Agreed Procedures, the findings of  the Panel that were not challenged in the context of the Arbitration are deemed  to form an integral part of the Award. The Arbitrators recommended that T&uuml;rkiye  bring into conformity with its obligations under the GATT 1994 its measures  that were found to be inconsistent in this Award and in the Panel&nbsp;Report  as modified by this Award. </p>

          </div>
      </div>
  </div>
</div>

    <p class="paranormaltext">In the agreed procedures for arbitration under  Article 25 of the DSU, the parties agreed to &ldquo;abide by the arbitration  award, which shall be final&rdquo;.</p>
    <p class="paranormaltext">&nbsp;</p>
    <h3>Reasonable period of  time</h3>
    <p> On 18 August  2022, T&uuml;rkiye informed the DSB that it intended to implement the recommendations  and rulings of the arbitrators  and the panel in this  dispute in a manner that respects its WTO obligations and that it would need a  reasonable period of time to do so. </p>
    <p>On  14 November 2022, the European Union and T&uuml;rkiye informed the DSB that in light  of ongoing discussions between the parties and  in order to allow them sufficient  time to discuss a mutually agreed period, they had agreed on a common  understanding regarding the deadlines relative to the arbitration procedure  provided in Article 21.3(c) of the DSU. </p>
    <p>On 10 January 2023, the European Union and T&uuml;rkiye  informed the DSB that they had agreed, pursuant to Articles 21.3(b) and  25.4 of the DSU,  that the reasonable period of time for T&uuml;rkiye to implement the recommendations  of the award of the arbitrator would expire on 25 April 2023.</p>
    <p>On 5 May 2023, T&uuml;rkiye  and the European Union informed the DSB of Agreed  Procedures under Articles 21 and 22 of the DSU (sequencing agreement).</p>
    <p>&nbsp;</p>
    <h3>Implementation of arbitration  Award </h3>
    <p align="left">
      On 25 April 2023, T&uuml;rkiye  informed the DSB pursuant to Article 21.6 of the  DSU that it had taken steps that brought it into  compliance with the arbitration award. These steps were: (i)&nbsp;the  publication of  a new Drug Reimbursement Regulation replacing  the previously applicable regulation that  entered into force on 25 August 2022, (ii) the adoption of a recommendation to initiate the  application process for relevant pharmaceutical companies regarding the  re-activation of their products in the reimbursement system, (iii)  the preparation of a new draft  Alternative Drug Reimbursement Regulation and (iv) the ongoing preparation of amendments  to the Guideline for Working Principles and Procedures of Human Medicinal  Products Priority Assessment Commission. On  19 May 2023, T&uuml;rkiye further informed the DSB  that the new Alternative Drug Reimbursement Regulation was published on 12 May  2023.</p>
<p>&nbsp;</p>
<p class="paranormaltext">&nbsp;</p>

</div>
<div class="rightCol">
<h2 class="h3 mt0">Share</h2>
<script type="text/javascript">showShareButton();</script>
<hr>
<div id="followDisputeBox"><h2 class="h3 mt0">Follow this dispute</h2>
    <button id="btnSendEmailAlertGrey" class="btn btn-faint" type="button" data-content="Please log on to follow this dispute and create email alerts." data-original-title="" data-placement="top" data-toggle="popover" title="">Send me email alerts</button></div>
        <script language="javascript1.2" type="text/javascript">
		if (verifyUserRoles('Secretariat#PUBLIC#DOL-R-WTO#EXTERNAL-MEDIA#DOL-R-OBS')){
				var membersbox = document.getElementById("followDisputeBox");
				membersbox.style.display = "block";
				$.ajax({
					dataType : 'html',
					cache    : false,
					url      : '/english/tratop_e/dispu_e/follow_individual_dispute_e.htm',
					success  : function(data) {
						$("#followDisputeBox").html( $('#fDsModal', $(data)) );
						var titleDS= "<h3>"+ds_array[dsNumber].code+": "+ds_array[dsNumber].title+"</h3>"; 
						titleDS = $("#ds_title").html(titleDS);
					}
				});
			}
			else{				var membersbox = document.getElementById("followDisputeBox");
				membersbox.style.display = "block";
			}
            </script>
<!-- display upcoming open hearings box if there are open hearings for this dispute -->	
<div  id="openhearingDiv">
</div>
<script>
	insertDisputeOpenHearings(dsNumber);
</script>

<script language="JavaScript1.2" type="text/javascript">
<!--  // call javascript function to display links to othere disputes with same countries or subjects
	seeAlsoLinks(dsNumber);
//-->
</script><p>
&nbsp;&nbsp;</p>
        <div class="panel panel-default panel-problems">
    <div class="panel-body">
        <p><strong>Problems viewing this page?</strong> If so, please contact <a href="javascript:emailWTO('webmaster@wto.org', 'WTO error - Problem with page')" class="link-blue"><span class="__cf_email__" data-cfemail="d9aebcbbb4b8aaadbcab99aeadb6f7b6abbe">[email&#160;protected]</span></a> giving details of the operating system and web browser you are using.</p>
    </div>
</div></div>
</div>
<form action="http://docsonline.wto.org/imrd/gen_redirectSearch.asp" method="post" name="hiddenform" target="new">
    <input type="hidden" name="query" value>
	<input type="hidden" name="language" value>
</form>

</div>   <!-- end of main page content -->
<!-- Display the footer on the page -->
<div id="footer"> 
</div> <!-- end of footer -->
</div>
<div id="lightbox" class="lightbox" style="position:fixed; top:0px; left:0px; width:100%; height:100%" tabindex="0" onClick="javascript:hideLightBox()"></div>
<!-- call javascript library for drop down menus -->
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script language="javascript1.2" src="/library/wtomenus/loader_wide_2011.js" type="text/javascript"></script>
<script>
$("#btnSendEmailAlertGrey").click(function() {
	window.location.href="/login_e.aspx?caller="+currentPageURL;
});
</script>
<script>
	var dolquery = "DataSource=Cat&query=@Symbol=WT/DS" + dsNumber + "/*";
	get_generic_html_dol_script(dolquery,"1","dolDocsBox","English", "title#<br>#symbol_link#|#date_bold");	onePageSumLinks(dsNumber);
	buildKeyfactsTbl(dsNumber);
</script>
<!-- hidden layer for rollover text -->
<div id="navtxt" class="tooltiptext" style="position:absolute; top:-100px; left:0px; visibility:hidden"></div>
<script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9839a7ee5c411836',t:'MTc1ODYyNjQ2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body>
</html>